polyradiculoneuropathy associated with IgG/IgA/IgM monoclonal gammopathy without known antibodies

Summary

polyradiculoneuropathy associated with IgG/IgA/IgM monoclonal gammopathy without known antibodies (MONDO:0016171) is a disease. A subtype of polyradiculoneuropathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	polyradiculoneuropathy associated with IgG/IgA/IgM monoclonal gammopathy without known antibodies
Mondo ID	MONDO:0016171
Orphanet	208981
GARD	0020411
Is cancer (heuristic)	no

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral neuropathy › polyneuropathy › polyradiculoneuropathy › polyradiculoneuropathy associated with IgG/IgA/IgM monoclonal gammopathy without known antibodies

Related subtypes (3): polyradiculopathy, chronic inflammatory demyelinating polyradiculoneuropathy, chronic polyradiculoneuritis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.